The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma
暂无分享,去创建一个
Shaji K. Kumar | M. Talpaz | A. Guenther | E. Ocio | Sheeba K. Thomas | M. Raab | Sylvia Zhao | N. Hohmann | Y. Goh | F. Xiang | Carl Simon | K. Vanasse | K. G. Vanasse | Fang Xiang | S. Thomas
[1] Michael D. Robbins,et al. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma , 2018, The New England journal of medicine.
[2] M. Dimopoulos,et al. Pomalidomide (POM), bortezomib, and low‐dose dexamethasone (PVd) vs bortezomib and low-dose dexamethasone (Vd) in lenalidomide (LEN)-exposed patients (pts) with relapsed or refractory multiple myeloma (RRMM): Phase 3 OPTIMISMM trial. , 2018 .
[3] J. Fay,et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. , 2017, Blood.
[4] M. Boccadoro,et al. Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma , 2017, Expert Review of Anticancer Therapy.
[5] M. Mehra,et al. Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD. , 2016, The oncologist.
[6] Carlos Ortiz-de-Solorzano,et al. The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care , 2016, Clinical Cancer Research.
[7] G. Caponigro,et al. Abstract 4630: The pan-PIM inhibitor PIM447 enhances the antitumor activity of lenalidomide in multiple myeloma cells via synergistic inhibition of c-MYC , 2016 .
[8] Alex M. Fichtenholtz,et al. Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. , 2016, Blood.
[9] S. Jagannath,et al. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. , 2016, Blood.
[10] A. Kassim,et al. Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity , 2016, Bone Marrow Transplantation.
[11] Yumin Dai,et al. Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies. , 2015, Journal of medicinal chemistry.
[12] J. Tamburini,et al. Control of Pim2 kinase stability and expression in transformed human haematopoietic cells , 2015, Bioscience reports.
[13] M. Raab,et al. Targeting the Pim kinases in multiple myeloma , 2015, Blood Cancer Journal.
[14] J. Laubach,et al. Management of relapsed multiple myeloma after autologous stem cell transplant. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[15] W. Klapper,et al. Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study , 2015, Haematologica.
[16] M. Dimopoulos,et al. Current treatment landscape for relapsed and/or refractory multiple myeloma , 2015, Nature Reviews Clinical Oncology.
[17] A. Khwaja,et al. PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways , 2014, British journal of haematology.
[18] H. Handa,et al. Structure of the human Cereblon–DDB1–lenalidomide complex reveals basis for responsiveness to thalidomide analogs , 2014, Nature Structural &Molecular Biology.
[19] Allan Wu,et al. AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. , 2014, Blood.
[20] Audrey Kauffmann,et al. Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers , 2014, Clinical Cancer Research.
[21] Christopher J. Ott,et al. The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins , 2014, Science.
[22] R. Orlowski,et al. Biological effects of the Pim kinase inhibitor, SGI-1776, in multiple myeloma. , 2013, Clinical lymphoma, myeloma & leukemia.
[23] Jianjun Yu,et al. Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation. , 2013, Blood.
[24] A. Kraft,et al. Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice , 2013, Journal of Hematology & Oncology.
[25] P. L. Bergsagel,et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. , 2011, Blood.
[26] Varsha Gandhi,et al. Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia. , 2011, Blood.
[27] I. Endo,et al. The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells , 2011, Leukemia.
[28] M. Nawijn,et al. For better or for worse: the role of Pim oncogenes in tumorigenesis , 2011, Nature Reviews Cancer.
[29] Stefan Knapp,et al. PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers , 2010, Haematologica.
[30] J. Blenis,et al. Molecular mechanisms of mTOR-mediated translational control , 2009, Nature Reviews Molecular Cell Biology.
[31] Michael Branson,et al. Critical aspects of the Bayesian approach to phase I cancer trials , 2008, Statistics in medicine.
[32] B. Barlogie,et al. International uniform response criteria for multiple myeloma , 2006, Leukemia.
[33] D. Esseltine,et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. , 2005, Blood.
[34] B. Farmer,et al. Expression, purification, crystallization and preliminary crystallographic analysis of human Pim-1 kinase. , 2005, Acta crystallographica. Section F, Structural biology and crystallization communications.
[35] Jos Jonkers,et al. Mice Deficient for All PIM Kinases Display Reduced Body Size and Impaired Responses to Hematopoietic Growth Factors , 2004, Molecular and Cellular Biology.
[36] L. Chodosh,et al. The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. , 2003, Genes & development.
[37] Anton Berns,et al. High-throughput retroviral tagging to identify components of specific signaling pathways in cancer , 2002, Nature Genetics.
[38] S Zacks,et al. Cancer phase I clinical trials: efficient dose escalation with overdose control. , 1998, Statistics in medicine.
[39] A. Berns,et al. Proviral tagging in E mu‐myc transgenic mice lacking the Pim‐1 proto‐oncogene leads to compensatory activation of Pim‐2. , 1995, The EMBO journal.
[40] A. Berns,et al. Predisposition to lymphomagenesis in pim-1 transgenic mice: Cooperation with c-myc and N-myc in murine leukemia virus-induced tumors , 1989, Cell.
[41] Wim Quint,et al. Murine leukemia virus-induced T-cell lymphomagenesis: Integration of proviruses in a distinct chromosomal region , 1984, Cell.